Hollister and Heavy Grass Collaborate with Slipknot Co-Founder Shawn "Clown" Crahan on New HashBone Line

Crahan is a multi-platinum, Grammy-winning artist who has sold more than 30 million albums. Clown's signature HashBone pre-roll packs will mark the first co-branded release from the Hollister-Heavy Grass licensing agreement. The products will initially be launched on May 17th in select dispensaries in California and on DreamyDelivery.com .

Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the " Company ", " Hollister Cannabis Co. " or " Hollister ") and Heavy Grass have partnered with Slipknot co-founder Shawn "Clown" Crahan for special-edition HashBone packs featuring six half-gram pre-rolls and matches in a soft-touch matte black case. The multi-platinum, Grammy-winning artist has sold more than 30 million records with Slipknot, whose last three albums debuted at No. 1 on both the Billboard 200 and the U.K. Albums Chart.

Hollister Biosciences Inc. (CNW Group/Hollister Biosciences Inc.)

Branded with original artwork, Clown's signature HashBone line contains a potent uplifting blend of 75% indica flower and 25% Paradise Citrus bubble hash. The signature premium indica flower features an earthy citrus-rich flavor profile with sublime sedating effects. Paradise Citrus, made from crossing Tropicana Cookies and Tina, adds another layer of full-body relaxation with happy head highs and citrusy notes of orchard-fresh sour orange. Lab testing confirms the potency of these hash-infused pre-rolls with THC levels above 40%.

Shawn "Clown" Crahan is a multi-talented artist who co-founded Slipknot, directed most of its music videos and serves as one of the primary songwriters. Clown is also the creative force behind Slipknot's iconic visuals, originating the masks and uniforms, creating album covers, packaging, live staging and visuals, and all merchandise.

Heavy Grass is a California cannabis brand with deep roots in the hard rock and heavy metal music community. In 2020 (see press release dated July 28, 2020 ), Hollister entered into a licensing agreement with Heavy Grass to produce and sell co-branded cannabis products primarily through collaborations with its music partners. HashBone, a leading hash-infused pre-roll in California , is one of Hollister's signature products, and the Clown HashBone line represents the first collaborative release between Hollister , Heavy Grass and one of its artists.

"We are very excited to be launching our HashBone collaboration with Clown. We couldn't ask for a better partner and someone who is true to the plant. This partnership is our first step in combining hard rock/metal with cannabis in a truly authentic way," says Carl Saling , the Co-Founder, CEO and Director of Hollister Biosciences. "Additionally, we are happy that we get to bring Clown to market in tandem with our friends at Heavy Grass - leveraging their experience in music-inspired cannabis products will amplify our overall marketing efforts."

Clown, a long-time cannabis connoisseur, is also an advocate for its potential therapeutic benefits. He adds, "Just remember, it's medicine."

In celebration of the release of Clown Cannabis, Clown and Heavy Grass are offering a once in a lifetime Green Ticket experience. The winner of Clown's Green Ticket will receive unlimited entrance for two into any Slipknot shows in the world for the next three years. For entry details visit theheavygrass.com .

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state company with a portfolio of innovative, high-quality cannabis & hemp branded consumer products and white-labeling manufacturing. Our products are sold in 370 dispensaries across Arizona and California . Hollister Biosciences wholly-owned brand, Venom Extracts, is a category-leading brand that sold more than 4 million grams in 2020, accounting for up to 30 percent of category sales in Arizona .

Products from Hollister Biosciences Inc. include HashBone, the brand's premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products and full-spectrum high CBD pet tinctures. Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA , birthplace of the "American Biker".

Website:   www.hollisterbiosciences.co , www.hollistercannabisco.com
  Instagram: @hashbones @hollistercannabisco

About Heavy Grass
Heavy Grass is a California cannabis brand that honors the legacy and lifestyle of heavy music by plugging in, getting loud and blazing up. We work with top California cultivators to provide both high quality and high potency products to our fans at an affordable price.  We want fans to spend money on a good time, not overpriced weed. www.theheavygrass.com | @heavygrassofficial

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed "forward-looking statements". The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "would", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/hollister-and-heavy-grass-collaborate-with-slipknot-co-founder-shawn-clown-crahan-on-new-hashbone-line-301292616.html

SOURCE Hollister Biosciences Inc.

Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/May2021/17/c2088.html

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)

Right Season is Unaware of Any Material Change

(TheNewswire)

Right Season Investments Corp.

May 28, 2025 TheNewswire - Vancouver, British Columbia Right Season Investments Corp. (TSXV: LITT ), (" Right Season " or the " Company "). At the request of the Canadian Investment Regulatory Organization, the Company wishes to confirm that its management is unaware of any material change in the Company's operations that would account for the recent increase in market activity.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less

CSE Bulletin: Delist - Better Plant Sciences Inc.

The common shares of Better Plant Sciences Inc. will be delisted from the CSE at market close today, May 27, 2025.

Better Plant Sciences is currently suspended. See Bulletin 2024-0121.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference

Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference

COMPASS Pathways Plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference at 10:30 am ET on May 20 th , 2025.

A live audio webcast of the presentation will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Glowing mushrooms with colorful graphs in the background on a dark surface.

US Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025

When the US Food and Drug Administration (FDA) rejected Lykos Therapeutics’ new drug application for MDMA-assisted therapy last August, the initial disappointment cast a shadow over the psychedelics industry.

However, the sector is seeing a resurgence of optimism in 2025 on the back of various US developments.

“The psychedelic industry in 2025 will likely see significant advancements in clinical applications, particularly in treating PTSD, depression, and addiction, as research continues to validate their therapeutic potential,” Dr. Markus Ploesser, chief innovation officer at Open Mind Health, told Microdose in January.

Keep reading...Show less
Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights

Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights

Highlights:

  • 6-week top-line data from Part A of COMP005 phase 3 trial in treatment resistant depression on track for late June
  • Phase 3 COMP006 in TRD on track for 26-week data second half of 2026
  • Cash position of $260.1 million at March 31, 2025
  • Conference call on May 8 at 8:00 am ET (1:00 pm UK)

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

COMPASS Pathways Plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into a strategic collaboration with HealthPort, a multi-site comprehensive community health organization. HealthPort employs an integrated model centered around social determinants of health and this collaboration will help inform the potential delivery of COMP360 synthesized psilocybin treatment in underserved communities, if FDA approved. This agreement with HealthPort expands the set of collaborations that Compass has established representing a broad spectrum of settings where people living with treatment resistant depression (TRD) receive their care in the United States.

HealthPort offers an integrated model of care aimed at helping those with behavioral health conditions and people impacted by poverty, disability and trauma. HealthPort is an evidence-based practice supporting thirteen dimensions of social determinants of health, including the coordination of an integrated outpatient mental health and addictions health clinic. HealthPort has been operating facility, residential, and mobile based interventions of care in the lower Eastern Shore of Maryland for the past 45 years.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×